Form 6-K GSK plc For: Jul 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
GSK halts camlipixant development for chronic cough after mixed results
July 17, 2026 6:55 AM EDTGSK plc (NYSE: GSK) announced it will not advance camlipixant, a P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) after mixed results from two phase III clinical trials.
The CALM-1 trial met its primary endpoint, showing statistically significant reductions in 24-hour cough... More
